Jump to content

Heated Chemotherapy HITHOC and HIPEC

From WikiMesothelioma — Mesothelioma Knowledge Base
Heated Chemotherapy Profile
HITHOC (Pleural) & HIPEC (Peritoneal)
Category Treatment
Temperature Range 40–43°C
Primary Agent Cisplatin
HITHOC Survival 20.5 months (median)
HIPEC Survival 53 months (median)
HIPEC 5-Year OS 47%
Perfusion Duration 60–120 minutes
30-Day Mortality 2–4%
Free Case Review →

Heated chemotherapy represents one of the most significant advances in mesothelioma treatment, combining cytoreductive surgery with high-concentration chemotherapy solutions heated to 40–43°C and circulated directly within the body cavity where the tumor originated. Two distinct procedures have emerged for the two primary forms of mesothelioma: Hyperthermic Intrathoracic Chemotherapy (HITHOC) for pleural mesothelioma and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for peritoneal mesothelioma.[1][2]

The scientific rationale is compelling: hyperthermia selectively destroys cancer cells at temperatures that normal tissue can tolerate, while simultaneously increasing drug penetration from approximately 1–2 mm to up to 5 mm into tumor tissue. For pleural mesothelioma, a National Cancer Database analysis of 3,232 patients found HITHOC independently improved overall survival (HR 0.80, p=0.002), with a median of 20.5 months versus 16.8 months without HITHOC. For peritoneal mesothelioma, CRS-HIPEC has transformed outcomes from a median survival of under 12 months to 53 months in the landmark multi-institutional registry, with 5-year survival rates reaching 47%.[3][4][5]

At experienced high-volume centers, 30-day mortality for both HITHOC and HIPEC ranges from 2% to 4%, and patients achieving complete cytoreduction with HIPEC have achieved median survival exceeding 10 years. The completeness of tumor removal and histologic subtype remain the most powerful predictors of outcome for both procedures.[6][7]

Heated chemotherapy at a glance:

  • HITHOC versus HIPEC — HITHOC perfuses heated chemotherapy into the thoracic cavity for pleural mesothelioma; HIPEC targets the abdominal cavity for peritoneal mesothelioma[1]
  • Temperature window — perfusion at 40–43°C selectively kills cancer cells while normal tissue tolerates up to 45°C[8]
  • Drug penetration boost — hyperthermia increases cisplatin tissue penetration from 1–2 mm to approximately 5 mm into tumor deposits[9]
  • HITHOC survival data — NCDB propensity-matched study of 3,232 patients showed 20.5-month median survival with HITHOC versus 16.8 months without (HR 0.80, p=0.002)[3]
  • CRS-HIPEC landmark results — 405-patient multi-institutional registry achieved 53-month median survival and 47% 5-year overall survival[4]
  • Complete cytoreduction — CC-0/CC-1 resection with cisplatin HIPEC at Wake Forest produced 127-month median survival versus 3 months for incomplete resection[6]
  • PCI scoring threshold — patients with Peritoneal Cancer Index of 20 or below achieved 119-month median survival versus 39 months for PCI above 20[10]
  • Cisplatin dosing caution — high-dose cisplatin above 125 mg/m2 carries 2.7-fold higher risk of renal insufficiency (p=0.006)[11]
  • Peritoneal perfusion protocols — HIPEC typically runs 90–120 minutes with cisplatin 200–250 mg/m2; HITHOC runs 60–90 minutes with cisplatin 80–125 mg/m2[12]
  • Immunotherapy synergy — preclinical 2024 data demonstrates HITHOC enhances T-cell infiltration and response to dual PD-1/CTLA-4 checkpoint blockade[13]

Key Facts

Key Facts: Heated Chemotherapy for Mesothelioma
  • Two procedures: HITHOC targets pleural mesothelioma; HIPEC targets peritoneal mesothelioma
  • Temperature range: 40–43°C — cancer cells die at these temperatures while normal cells survive up to 45°C
  • Drug penetration: Heat increases chemotherapy tissue penetration from 1–2 mm to up to 5 mm
  • Primary agent: Cisplatin is the most commonly used chemotherapy drug in both HITHOC and HIPEC
  • HITHOC survival benefit: 20.5 months vs. 16.8 months median OS in NCDB study of 3,232 patients (HR 0.80)
  • HIPEC landmark data: 53-month median survival and 47% 5-year survival in 405-patient multi-institutional registry
  • Best HIPEC outcomes: Complete cytoreduction (CC-0) achieves 94-month median survival; CC-0/1 with cisplatin at Wake Forest: 127 months
  • Largest HITHOC study: German multicenter registry of 350 patients across 4 university centers
  • Mortality rates: 2–4% at high-volume centers for both procedures
  • Patient selection: Epithelioid histology, good performance status (ECOG 0–1), and achievable complete resection are required
  • Immunotherapy synergy: Preclinical 2024 data shows HITHOC enhances T-cell infiltration and response to checkpoint inhibitors
  • Perfusion duration: HITHOC typically 60–90 minutes; HIPEC typically 90–120 minutes

What Is the Scientific Basis for Heated Chemotherapy?

The combination of hyperthermia and cytotoxic drugs produces cancer cell killing that exceeds what either treatment achieves alone. This synergism operates through multiple mechanisms that researchers have identified over decades of laboratory and clinical investigation.[1][14]

Hyperthermia disrupts tumor cell membranes, increasing their permeability and allowing chemotherapy agents to penetrate deeper into tissue. At normothermic temperatures (37°C), cisplatin penetrates approximately 1–2 mm into tumor deposits, but at hyperthermic temperatures (42°C), penetration increases to approximately 5 mm. This enhanced drug uptake is critical because mesothelioma typically grows as a diffuse sheet across serosal surfaces rather than as discrete nodules.[9][2]

Cancer cells are selectively vulnerable to heat in the 41–43°C range due to increased lysosomal enzyme activity specific to malignant cells. Normal cells tolerate temperatures up to approximately 45°C, creating a therapeutic window. Hyperthermia also depresses oxidative metabolism in tumor cells, causing accumulation of lactic acid and decreased pH in the tumor microenvironment, which further accelerates cell death. Additionally, heat reduces chemoresistance — a major clinical problem in mesothelioma — by amplifying the cytotoxic effect of cisplatin even at temperatures below 42°C.[1][8]

"The highest thermal enhancement ratios have been observed for alkylating agents such as cisplatin, melphalan, and cyclophosphamide — the very drugs most commonly used in intraoperative perfusion protocols for mesothelioma."
— David Foster, Patient Advocate, Danziger & De Llano

How Does HITHOC Work for Pleural Mesothelioma?

HITHOC is performed immediately following cytoreductive surgery for pleural mesothelioma, most commonly pleurectomy/decortication (P/D). After the surgeon removes all visible tumor from the chest cavity, a heated chemotherapy solution is circulated through the thoracic space using a closed-circuit perfusion system. The goal is to destroy microscopic residual cancer cells that surgery alone cannot remove.[11][15]

In the German multicenter study — the largest HITHOC dataset worldwide — 350 patients were treated across four university centers (Regensburg, Munich, Heidelberg, Freiburg) from 2008 to 2019. Extended P/D was the most common surgical approach (75% of cases), followed by standard P/D (22%) and EPP (3%). Macroscopic complete resection was achieved in 86% of patients. Additional structures resected included the diaphragm (65.7%), pericardium (44.6%), and chest wall (10%).[11][16]

Dosing Protocols

Cisplatin is the primary chemotherapy agent used in HITHOC, administered either alone or combined with doxorubicin:[11]

Regimen Patients Dosing
Cisplatin alone 61% Median 108.8 mg/m² (range 51–200 mg/m²)
Cisplatin + doxorubicin 39% Cisplatin 108.8 mg/m² + doxorubicin 46.9 mg/m²
Low-dose cisplatin (≤125 mg/m²) 67% Reduced nephrotoxicity risk
High-dose cisplatin (>125 mg/m²) 33% 2.7× higher renal insufficiency risk (p=0.006)

Perfusion is typically performed for 60–90 minutes at a maximum temperature of 42°C with a perfusion volume of approximately 5,000 mL. An Egyptian comparative trial used cisplatin at 125 mg/m² infused for 70 minutes at 40–43°C.[17][18]

Survival Outcomes

Multiple studies have demonstrated a survival advantage for HITHOC when added to cytoreductive surgery:[3][19]

Study Patients With HITHOC Without HITHOC Significance
NCDB propensity-matched (2023) 3,232 (365 HITHOC) 20.5 months 16.8 months HR 0.80, p=0.002
Systematic review (2025) 7 studies 13–35 months 11–22.8 months 6 of 7 studies showed benefit
Randomized pilot (2021) 27 28 months 19 months HR 0.77
Epithelioid subgroup (pilot) subset 45 months 15 months 3× survival advantage

The largest analysis — a propensity-score matched study using the National Cancer Database — demonstrated that HITHOC was independently associated with improved overall survival and, notably, decreased 30-day mortality (3.2% vs. 6.0%, p=0.017) despite increased length of stay (12 vs. 7 days).[3][20]

Immunomodulatory Effects

Preclinical research published in 2024 demonstrated that HITHOC remodels the tumor immune microenvironment by promoting T-cell infiltration and enhancing immune checkpoint expression. In murine models, HITHOC synergized with dual PD-1 and CTLA-4 inhibition, providing a scientific rationale for combining HITHOC with immunotherapy in future clinical trials.[13]

How Does HIPEC Work for Peritoneal Mesothelioma?

CRS-HIPEC has transformed peritoneal mesothelioma from a rapidly fatal disease with median survival of 6–16 months into one where long-term survival exceeding 10 years is achievable in selected patients. The procedure involves maximal cytoreductive surgery to remove all visible tumor deposits from the peritoneal surfaces, followed by perfusion of the abdominal cavity with heated chemotherapy.[12][6]

The Peritoneal Cancer Index

The Peritoneal Cancer Index (PCI), developed by Sugarbaker, is the standard method for quantifying peritoneal disease burden before and during surgery. The abdomen is divided into 13 regions — 9 abdominal regions (numbered 0–8 in clockwise fashion) plus 4 small bowel segments (upper/lower jejunum, upper/lower ileum). Each region receives a Lesion Size score from 0 (no tumor) to 3 (>5 cm or confluence), producing a total PCI score from 0 to 39.[12][21]

PCI profoundly impacts prognosis: patients with PCI ≤20 achieved a median overall survival of 119 months, compared to only 39 months when PCI exceeded 20. At Wake Forest Baptist Medical Center — one of the world's highest-volume centers with 28 years of experience and 111 peritoneal mesothelioma patients — the mean PCI at first CRS-HIPEC was 18.7.[6][10]

Completeness of Cytoreduction

The completeness of cytoreduction (CC) score is the single most powerful predictor of survival after CRS-HIPEC:[12][4]

CC Score Residual Disease Median Survival
CC-0 No visible disease 94 months
CC-1 Nodules <2.5 mm 67 months
CC-2 Nodules 2.5 mm–2.5 cm 40 months
CC-3 >2.5 cm or confluence 12 months

CC-0 and CC-1 are considered complete cytoreductions because residual nodules ≤2.5 mm are thought to be penetrable by the heated intraperitoneal chemotherapy. At Wake Forest, patients achieving R0-R1 complete cytoreduction had a median overall survival of 127 months — more than 10 years — versus only 3.0 months for R2c (incomplete) resections.[6][22]

HIPEC Agents and Protocols

Agent Dosing Duration Notes
Cisplatin 200–250 mg/m² 90 min Currently preferred first-line agent
Cisplatin + doxorubicin 50–100 + 15–45 mg/m² 90 min Better OS (HR 0.54) in RENAPE study
Mitomycin C 30–40 mg/m² 90–120 min Earlier standard; inferior to cisplatin
Carboplatin 500–1,000 mg/m² 90 min Occasional alternative

The Wake Forest group demonstrated that switching from mitomycin C to cisplatin significantly improved outcomes: median OS of 42.4 months with cisplatin versus 11.6 months with mitomycin C (p=0.007). The RENAPE multicenter study (249 patients, 20 centers) showed that dual-agent HIPEC regimens achieved significantly better overall survival than single-agent regimens (HR 0.54, 95% CI 0.31–0.95) without increased major morbidity.[6][12]

Survival Data from Major Centers

Center/Registry Patients Median OS 5-Year OS
Multi-institutional (8 centers, Yan et al.) 405 53 months 47%
Wake Forest Baptist 111 39 months ~40%
3 US institutions (Alexander et al.) 211 38.4 months 41%
India tertiary center 15 27 months 33% (3-year)
Meta-analysis (20 studies) 1,047 19–92 months 42%

The multi-institutional registry by Yan et al. (2009), published in the Journal of Clinical Oncology and encompassing 405 patients from eight centers worldwide, remains the landmark dataset. Epithelioid subtype, absence of lymph node metastasis, CC-0/CC-1 resection, and HIPEC itself were all independently associated with improved survival.[4][23]

Who Is a Candidate for Heated Chemotherapy?

Patient selection is critical for both HITHOC and HIPEC, and treatment decisions should be made at specialized high-volume centers with multidisciplinary expertise.[11][12]

HITHOC Candidacy (Pleural Mesothelioma)

  • Performance status: ECOG 0–1 (95% of German HITOC cohort); Karnofsky index ≥80% (83% of cohort)
  • Histology: Epithelioid strongly preferred (85% of German cohort); biphasic considered selectively; sarcomatoid generally excluded
  • Disease stage: UICC stages I–III (98% of German cohort); stage IV only rarely considered
  • Surgical goal: Macroscopic complete resection must be achievable — HITHOC targets only microscopic residual disease
  • No distant metastases: Extra-thoracic spread is a contraindication
  • Age: Mean age 61.5 years in the German study; no strict cutoff but older patients require careful evaluation[11][24]

HIPEC Candidacy (Peritoneal Mesothelioma)

  • Performance status: ECOG 0–1 preferred; ECOG 2 considered cautiously; ECOG 3 associated with 13× higher mortality hazard
  • Histology: Epithelioid offers best outcomes (38–51 months median OS); biphasic may benefit if CC-0 achievable; sarcomatoid is a contraindication at most centers
  • PCI score: Lower PCI (≤20) strongly preferred — associated with 119-month vs. 39-month median survival
  • Complete resection: CC-0/CC-1 must be achievable; if only CC-2 or CC-3 expected, CRS-HIPEC is generally not performed with curative intent
  • No extra-abdominal metastases or positive lymph nodes
  • Age: Age <60 independently associated with favorable outcomes; average age 55 years at Wake Forest[6][25][26]

Contraindications

Heated chemotherapy is generally contraindicated in patients with sarcomatoid histologic subtype, extra-cavitary metastases, poor performance status (ECOG >2), inability to achieve macroscopic complete resection, or significant comorbidities precluding major surgery. For HIPEC specifically, extensive small bowel mesenteric involvement that prohibits adequate cytoreduction is an absolute contraindication. Patients with initially unresectable disease may be referred for neoadjuvant systemic chemotherapy to potentially downstage the tumor before reconsidering surgery.[12][20]

What Are the Complications and Risks?

Renal Toxicity

Cisplatin-induced nephrotoxicity is the most feared complication specific to heated chemotherapy. In the German HITHOC multicenter study, 12% of patients developed renal insufficiency overall, though only 1.4% required temporary dialysis. High-dose cisplatin (>125 mg/m²) increased the risk 2.7-fold (p=0.006) and was associated with a 12.2-fold higher likelihood of in-hospital mortality (p=0.001). For HIPEC, reported nephrotoxicity rates with cisplatin range from 3.7% to 36%, depending on dosing and renal protection protocols. Sodium thiosulfate, amifostine, and perioperative fluid balancing are used for renal protection, though no standardized protocol exists.[27][28][11]

Surgical Complications

For HITHOC, the German multicenter study reported an overall complication rate of 51%, with surgical revision required in 15% of patients for air leaks, hemothorax, chylothorax, or empyema. Pneumonia occurred in 15%, prolonged air leak (>7 days) in 11%, new atrial fibrillation in 12%, and respiratory insufficiency in 10%. The median ICU stay was 2 days and median hospital stay was 18 days.[11][29]

For HIPEC, the multi-institutional Yan et al. registry reported an overall complication rate of 46%, with 31% classified as grade 3–4 (severe). A meta-analysis of 20 studies found morbidity rates ranging from 8% to 90%, largely reflecting differences in institutional experience and learning curves.[4][12]

Mortality Rates

Setting 30-Day/In-Hospital Mortality
HITHOC (German multicenter, n=350) 3.7%
HITHOC (NCDB, n=365) 3.2%
HIPEC (Wake Forest, n=111 MPM) 2.7%
HIPEC (8-center registry, n=405) 2.0%
HIPEC (3 US centers, n=211) 2.3%

A 2025 systematic review found no reported mortality directly attributable to HITHOC-specific complications across all seven included studies. Deaths were attributed to surgical complications or pre-existing comorbidities rather than the heated perfusion itself.[19][30]

What Clinical Trials Are Investigating Heated Chemotherapy?

Active HITHOC Trials

An active registered trial (NCT05508555) is comparing pleurectomy/decortication with versus without HITHOC using cisplatin at 125 mg/m² infused for 70 minutes at 40–43°C for localized malignant pleural mesothelioma. The 2024 preclinical data demonstrating HITHOC synergy with dual PD-1/CTLA-4 blockade provides strong rationale for clinical combination trials with immunotherapy, which are anticipated.[17][13][11]

Active HIPEC Trials

Several HIPEC-related trials are ongoing or recently reported. An individualized HIPEC response assessment study is evaluating ex vivo mass response testing to personalize HIPEC agent selection for peritoneal carcinomatosis including mesothelioma. The INTERACT MESO phase I/II trial is investigating intraperitoneal paclitaxel for primary malignant peritoneal mesothelioma. A phase II trial (NTR7060) at Erasmus MC is evaluating adjuvant dendritic cell-based immunotherapy after CRS-HIPEC, with early results showing feasibility and T-cell memory activation. Novel approaches including PIPAC (pressurized intraperitoneal aerosol chemotherapy) are being studied as potential neoadjuvant strategies to downstage initially unresectable peritoneal mesothelioma.[31][32][12][33]

How Does Heated Chemotherapy Connect to Mesothelioma Compensation?

Patients diagnosed with mesothelioma who undergo HITHOC or HIPEC may be eligible for significant compensation through multiple pathways. The cost of these specialized procedures — which require treatment at experienced high-volume centers — combined with travel, extended hospital stays, and lost income creates substantial financial burden for patients and families.[23][34]

More than 60 active asbestos trust funds hold over $30 billion for mesothelioma victims, and patients can file claims with multiple trusts simultaneously. Mesothelioma lawsuits have produced some of the largest verdicts in personal injury law. An experienced mesothelioma attorney can help patients navigate the claims process while they focus on treatment and recovery. Veterans with service-connected asbestos exposure may also qualify for VA disability benefits and healthcare coverage.[35][36]


⚠ Statute of Limitations Warning: Filing deadlines vary by state from 1-6 years from diagnosis. Texas allows 2 years from diagnosis or discovery. Contact an attorney immediately to preserve your rights.

Free, Confidential Case Evaluation

Call (866) 222-9990 or visit dandell.com/contact-us

No upfront fees • Experienced representation • National practice

References

  1. ↑ 1.0 1.1 1.2 1.3 Hyperthermic Intraperitoneal Chemotherapy: Rationale and Technique, PMC / National Library of Medicine
  2. ↑ 2.0 2.1 Mesothelioma Treatment Options, Danziger & De Llano
  3. ↑ 3.0 3.1 3.2 3.3 Impact of Hyperthermic Intrathoracic Chemotherapy (HITHOC) During Resection of Pleural Mesothelioma on Patient Survival, Journal of Thoracic Disease (2023)
  4. ↑ 4.0 4.1 4.2 4.3 4.4 Cytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience, Journal of Clinical Oncology (2009)
  5. ↑ Mesothelioma Treatment Options, Mesothelioma Lawyer Center
  6. ↑ 6.0 6.1 6.2 6.3 6.4 6.5 6.6 Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center, Annals of Surgical Oncology (2023)
  7. ↑ Mesothelioma Treatment, Mesothelioma.net
  8. ↑ 8.0 8.1 Hyperthermic Intrathoracic Chemotherapy (HITHOC): Mechanisms and Clinical Application, PMC / National Library of Medicine
  9. ↑ 9.0 9.1 Optimal Hyperthermic Intraperitoneal Chemotherapy Regimen, PMC / National Library of Medicine
  10. ↑ 10.0 10.1 Cytoreductive Surgery and HIPEC for Peritoneal Mesothelioma: Outcomes from a Tertiary Cancer Care Center in India, Cureus
  11. ↑ 11.0 11.1 11.2 11.3 11.4 11.5 11.6 11.7 11.8 Hyperthermic Intrathoracic Chemotherapy (HITOC) after Cytoreductive Surgery: German Multicenter Study of 350 Patients, PMC / National Library of Medicine
  12. ↑ 12.0 12.1 12.2 12.3 12.4 12.5 12.6 12.7 12.8 Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma, PMC / National Library of Medicine
  13. ↑ 13.0 13.1 13.2 Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma, Cancer Immunology Research (2024)
  14. ↑ Hyperthermic Intrathoracic Chemotherapy (HITHOC), PMC / National Library of Medicine
  15. ↑ Multimodal Treatment of Pleural Mesothelioma with Cytoreductive Surgery and Hyperthermic Intrathoracic Chemotherapy, MDPI Cancers (2024)
  16. ↑ Mesothelioma Surgery, Mesothelioma Lawyer Center
  17. ↑ 17.0 17.1 Effect of Intraoperative Hyperthermic Intrathoracic Chemotherapy After Pleurectomy Decortication for MPM: A Comparative Study, Updates in Surgery (2024)
  18. ↑ Intraoperative Hyperthermic Intrathoracic Chemotherapy After Pleurectomy Decortication for Malignant Pleural Mesothelioma, PMC / National Library of Medicine (2024)
  19. ↑ 19.0 19.1 Hyperthermic Intrathoracic Chemotherapy in Patients with Malignant Pleural Mesothelioma: A Systematic Review, World Journal of Surgical Oncology (2025)
  20. ↑ 20.0 20.1 Mesothelioma Treatment Overview, MesotheliomaAttorney.com
  21. ↑ Peritoneal Mesothelioma, Danziger & De Llano
  22. ↑ Peritoneal Mesothelioma, Mesothelioma Lawyer Center
  23. ↑ 23.0 23.1 Mesothelioma Compensation, Danziger & De Llano
  24. ↑ Treatment Eligibility and Candidacy, Mesothelioma.net
  25. ↑ Patient Selection Criteria for HIPEC, Dr. Oracle
  26. ↑ Treatment Eligibility for Mesothelioma Patients, Mesothelioma Lawyer Center
  27. ↑ Nephrotoxicity Associated with Cytoreductive Surgery Combined with HIPEC, PMC / National Library of Medicine
  28. ↑ Bidirectional Intraoperative Chemotherapy Using Cisplatin and Ifosfamide, American Journal of Case Reports
  29. ↑ Mesothelioma Surgery Options, Danziger & De Llano
  30. ↑ Mesothelioma Surgery Options, Mesothelioma.net
  31. ↑ Ex Vivo Assessment of Cellular Mass Response for Personalized HIPEC Agent Selection, ASCO Abstract (2024)
  32. ↑ Adjuvant Dendritic Cell-Based Immunotherapy After CRS and HIPEC for Malignant Peritoneal Mesothelioma: Phase II Trial, PMC / National Library of Medicine
  33. ↑ Mesothelioma Clinical Trials, Danziger & De Llano
  34. ↑ Mesothelioma Compensation Guide, Mesothelioma Lawyer Center
  35. ↑ Asbestos Trust Funds, MesotheliomaAttorney.com
  36. ↑ Mesothelioma Compensation Guide, Mesothelioma.net

Cite error: <ref> tag with name "medrxiv_pilot" defined in <references> is not used in prior text.
Cite error: <ref> tag with name "pmc_alexander" defined in <references> is not used in prior text.
Cite error: <ref> tag with name "asco_roswell" defined in <references> is not used in prior text.
Cite error: <ref> tag with name "cancer_gov" defined in <references> is not used in prior text.

Retrieved from "https://wikimesothelioma.com/index.php?title=Heated_Chemotherapy_HITHOC_and_HIPEC&oldid=1565"